Michael Palfreyman
Michael Palfreyman
President, Palfreyman BioPharm Advisors
Verified email at torreypinesinv.com
Title
Cited by
Cited by
Year
Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways
CA Altar, P Laeng, LW Jurata, JA Brockman, A Lemire, J Bullard, ...
Journal of Neuroscience 24 (11), 2667-2677, 2004
3722004
Simultaneous determination of 3, 4‐dihydroxyphenylalanine, 5‐hydroxytryptophan, dopamine, 4‐hydroxy‐3‐methoxyphenylalanine, norepinephrine, 3, 4‐dihydroxyphenylacetic acid …
J Wagner, P Vitali, MG Palfreyman, M Zraika, S Huot
Journal of neurochemistry 38 (5), 1241-1254, 1982
3601982
The role of 5-HT2A receptors in antipsychotic activity
CJ Schmidt, SM Sorensen, JH Kenne, AA Carr, MG Palfreyman
Life sciences 56 (25), 2209-2222, 1995
2691995
The relationship between GABA concentrations in brain and cerebrospinal fluid
P Böhlen, S Huot, MG Palfreyman
Brain Research 167 (2), 297-305, 1979
2091979
NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations
JH Kehne, TC McCloskey, BM Baron, EM Chi, BL Harrison, JP Whitten, ...
European journal of pharmacology 193 (3), 283-292, 1991
1531991
Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with …
SH Preskorn, M Gawryl, N Dgetluck, M Palfreyman, LO Bauer, DC Hilt
Journal of Psychiatric Practice® 20 (1), 12-24, 2014
1372014
Electrophysiological, biochemical and behavioral evidence for 5-HT 2 and 5-HT 3 mediated control of dopaminergic function
MG Palfreyman, CJ Schmidt, SM Sorensen, MW Dudley, JH Kehne, ...
Psychopharmacology 112 (1), S60-S67, 1993
1361993
The pharmacology of GABA-transaminase inhibitors
MG Palfreyman, PJ Schechter, WR Buckett, GP Tell, J Koch-Weser
Biochemical pharmacology 30 (8), 817-824, 1981
1361981
Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships
IA McDonald, JM Lacoste, P Bey, MG Palfreyman, M Zreika
Journal of medicinal chemistry 28 (2), 186-193, 1985
1321985
Activity of 5, 7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site.
BM Baron, BL Harrison, FP Miller, IA McDonald, FG Salituro, CJ Schmidt, ...
Molecular pharmacology 38 (4), 554-561, 1990
1291990
Determination of dopa, dopamine, dopac, epinephrine, norepinephrine, α-monofluoromethyldopa and α-difluoromethyldopa in various tissues of mice and rats using reversed-phase …
J Wagner, M Palfreyman, M Zraika
Journal of Chromatography B: Biomedical Sciences and Applications 164 (1), 41-54, 1979
1261979
Effect of acute and chronic MDL 73,147 EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons
SM Sorensen, TM Humphreys, MG Palfreyman
European journal of pharmacology 163 (1), 115-118, 1989
1021989
[3H] 5, 7-Dichlorokynurenic acid, a novel radioligand labels NMDA receptor-associated glycine binding sites
BM Baron, BW Siegel, AL Slone, BL Harrison, MG Palfreyman, SD Hurt
European Journal of Pharmacology: Molecular Pharmacology 206 (2), 149-154, 1991
741991
Relationship between extracellular 5‐hydroxytryptamine and behaviour following monoamine oxidase inhibition and l‐tryptophan
AJ Sleight, CA Marsden, KF Martin, MG Palfreyman
British journal of pharmacology 93 (2), 303-310, 1988
741988
(E)-. beta.-(Fluoromethylene)-m-tyrosine: a substrate for aromatic L-amino acid decarboxylase liberating an enzyme-activated irreversible inhibitor of monoamine oxidase
IA McDonald, JM Lacoste, P Bey, J Wagner, M Zreika, MG Palfreyman
Journal of the American Chemical Society 106 (11), 3354-3356, 1984
661984
History of serotonin and serotonin disorders.
A Sjoerdsma, MG Palfreyman
Annals of the New York Academy of Sciences, 1990
641990
Inhibition of monoamine synthesis by irreversible blockade of aromatic aminoacid decarboxylase with α-monofluoromethyldopa
MJ Jung, MG Palfreyman, J Wagner, P Bey, G Ribereau-Gayon, M Zraika, ...
Life sciences 24 (11), 1037-1042, 1979
641979
(E)-2-(3, 4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase
P Bey, J Fozard, JM Lacoste, IA McDonald, M Zreika, MG Palfreyman
Journal of medicinal chemistry 27 (1), 9-10, 1984
611984
Vigabatrin: mechanisms of action
MJ Jung
Antiepileptic drugs, 1995
561995
Inhibitors of lysyl oxidase
MG Palfreyman, P Bey, IA Mcdonald
US Patent 4,965,288, 1990
561990
The system can't perform the operation now. Try again later.
Articles 1–20